Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SaVIS study of investigational iNTS-GMMA vaccine in healthy adults
PACTR202310834458532Phase 1Not yet recruiting
- Sponsor
- University of Oxford
- Start
- Jan 2024
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1 trial of iNTS-GMMA vaccine in nontyphoidal salmonellosis (4 arms), sponsored by University of Oxford. Primary endpoints: Safety and reactogenicity of the iNTS-GMMA vaccine, Injection site tenderness and pain and 15 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
iNTS-GMMA vaccine
03
Conditions
nontyphoidal salmonellosis
Beyond the preview
Go deeper on PACTR202310834458532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202310834458532.